Study of in vitro and in vivo effects of the piperidine nitroxide Tempol - A potential new therapeutic agent for gliomas

European Journal of Cancer

Volumn 39, Issue 6, 2003, Pages 829-837

  Gariboldi, M B ^a   Ravizza, R ^a   Petterino, C ^c   Castagnaro, M ^c   Finocchiaro, G ^b   Monti, Elena ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c Dept Pub Hlth Compar Pathol/V ^*  (Italy)

Author keywords

Antitumour effects; Glioma; p21waf1 cip1; Tempol

Indexed keywords

ANTINEOPLASTIC AGENT; GENE PRODUCT; PROTEIN P21; PROTEIN P53; TEMPOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL COUNT; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG STABILITY; FEMALE; GLIOBLASTOMA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; TUMOR VASCULARIZATION; XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYCLIC N-OXIDES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUG SCREENING ASSAYS, ANTITUMOR; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASM TRANSPLANTATION; RATS; SPIN LABELS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037376807     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00742-6     Document Type: Article

References (28)

1. Levin V.A., Gutin P.H., Leibel S. Neoplasms of the central nervous system. De Vita V.T., Hellman S., Rosenberg S.A. Cancer Principles and Practice of Oncology. 1993;1697-1737 Lippincott, Philadelphia.
2. Hosli P., Sappino A.P., De Tribolet N., Dietrich P.Y. Malignant glioma. should chemotherapy be overthrown by experimental treatments? Ann. Oncol. 9:1996;589-600.
3. Gariboldi M.B., Lucchi S., Caserini C., Supino R., Oliva C., Monti E. Antiproliferative effect of the piperidine nitroxide TEMPOL on neoplastic and nonneoplastic mammalian cell lines. Free Rad. Biol. Med. 24:1998;913-923.
4. Gariboldi M.B., Rimoldi V., Supino R., Favini E., Monti E. The nitroxide TEMPOL induces oxidative stress, p21 WAF1/CIP1, and cell death in HL60 cells. Free Rad. Biol. Med. 29:2000;633-641.
5. Gomez-Manzano C., Fueyo J., Kyritsis A.P.et al. Characterization of p53 and p21 functional interactions in glioma cells en route of apoptosis. J. Natl. Cancer Inst. 89:1997;1036-1044.
6. Zhang R., Shohami E., Beit-Yannai E., Bass R., Trembovler V., Samuni A. Mechanism of brain protection by nitroxide radicals in experimental model of closed-head injury. Free Rad. Biol. Med. 24:1998;332-340.
7. Mitchell J.B., Wink D.A., DeGraff W., Gamson J., Keefer L.K., Krishna M.C. Hypoxic mammalian cells radiosensitization by nitric oxide. Cancer Res. 53:1993;5845-5848.
8. Alley M.C., Scudiero D.A., Monks A.et al. Feasibility of drug screening with panels of human tumour cell lines usin a microculture tetrazolium assay. Cancer Res. 48:1988;589-601.
9. United Kingdom Co-Ordinating Committee On Cancer Research (UKCCCR) Guidelines for the welfare of animals in experimental neoplasia [second edition] Br J Cancer 1998, 77, 1-10.
10. Assimakopoulou M., Sotiropoulou-Bonikou G., Maraziotis T., Papadakis N., Varakis I. Microvessel density in brain tumours. Anticancer Res. 17:1997;4747-4753.
11. Plate H.K. Gene therapy of malignant glioma via inhibition of tumour angiogenesis. Cancer Metast. Rev. 15:1996;237-240.
12. Monti E., Cova D., Guido E., Morelli R., Oliva C. Protective effect of the nitroxide Tempol against the cardiotoxicity of adriamycin. Free Rad. Biol. Med. 21:1996;463-470.
13. Samuni A., DeGraff W., Krishna M.C., Mitchell J.B. Cellular sites of H2O2-induced damage and their protection by nitroxides. Biochim. Biophys. Acta. 1525:2001;70-76.
14. Suy S., Mitchell J.B., Ehleiter D., Haimovitz-Friedman A., Kasid U. Nitroxides tempol and tempo induce divergent signal transduction pathways in MDA-MB 231 breast cancer cells. J. Biol. Chem. 273:1998;17871-17878.
15. Wang G., Godinger D., Aronovitch J., Samuni A. Opposing effects of nitroxide free radicals in Escherichia coli mutants deficient in DNA repair. Biochim. Biophys. Acta. 1305:1996;71-78.
16. Offer T., Russo A., Samuni A. The pro-oxidative activity of SOD and nitroxide SOD mimics. FASEB J. 14:2000;1215-1223.
17. 1. Science. 272:1996;719-722.
18. Russo T., Zambrano N., Esposito F.et al. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J. Biol. Chem. 270:1995;29386-29391.
19. Kokunai T., Tamaki N. Relationship between expression of p21WAF1/CIP1 and radioresistance in human gliomas. Jpn. J. Cancer Res. 90:1999;638-646.
20. Kondo S., Barna B.P., Kondo Y.et al. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene. 13:1996;1279-1285.
21. Hsiao M., Tse V., Carmel J.et al. Functional expression of human p21 (WAF1/CIP1) gene in rat glioma cells suppresses tumour growth in vivo and induces radiosensitivity. Biochem. Biophys. Res. Commun. 233:1997;329-335.
22. Baudet C., Chevalier G., Chassevent A.et al. 1,25-Dihydroxyvitamin D3 induces programmed cell death in a rat glioma cell line. J. Neurosci. Res. 46:1996;540-550.
23. Pourquier P., Montaudon D., Huet S., Larrue A., Clary A., Robert J. Doxorubicin-induced alterations of c-myc and c-jun gene expression in rat glioblastoma cells. role of c-jun in drug resistance and cell death Biochem. Pharmacol. 55:1998;1963-1971.
24. Hahn S.M., Tochner Z., Krishna C.M.et al. Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res. 52:1992;1750-1753.
25. Folkman J. What is the evidence that tumours are angiogenesis dependent? J. Natl. Cancer Inst. 82:1990;4-6.
26. Matsushita H., Morishita R., Kida I.et al. Inhibition of growth of human vascular smooth muscle cells by overexpression of p21 gene through induction of apoptosis. Hypertension. 31:1998;493-498.
27. Paulsen F., Hoffmann W., Becker G.et al. Chemotherapy in the treatment of recurrent glioblastoma multiforme. ifosfamide versus temozolomide J. Cancer Res. Clin. Oncol. 125:1999;411-418.
28. O'Reilly S.M., Newlands E.S., Glaser M.G.et al. Temozolomide. a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours Eur. J. Cancer. 29A:1993;940-942.